Expanding spectrum of anticancer drug, imatinib, in the disorders affecting brain and spinal cord

&NA; Imatinib is a tyrosine kinase inhibitor and is used as a first line drug in the treatment of Philadelphia‐chromosome‐positive chronic myeloid leukaemia and gastrointestinal stromal tumors. Being tyrosine kinase inhibitor, imatinib modulates the activities of Abelson gene (c‐Abl), Abelson related gene (ARG), platelet‐derived growth factor receptor (PDGFR), FMS‐like tyrosine kinase 3 (FLT3), lymphocyte‐specific protein (Lck), mitogen activated protein kinase (MAPK), amyloid precursor protein intracellular domain (AICD), &agr;‐synuclein and the stem‐cell factor receptor (c‐kit). Studies have shown the role of imatinib in modulating the pathophysiological state of a number of disorders affecting brain and spinal cord such as Alzheimer's disease, Parkinson's disease, stroke, multiple sclerosis and spinal cord injury. The present review discusses the role of imatinib in the above described disorders and the possible mechanisms involved in these diseases.

[1]  M. Tabaton,et al.  Generation of an Apoptotic Intracellular Peptide by γ-Secretase Cleavage of Alzheimer's Amyloid ß Protein Precursor , 2000 .

[2]  R. Cappai,et al.  6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes α-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation. , 2006, The Journal of Biological Chemistry.

[3]  K. Aho,et al.  Cerebrovascular disease in the community: results of a WHO collaborative study. , 1980, Bulletin of the World Health Organization.

[4]  J. Ma,et al.  c-Abl–p38α signaling plays an important role in MPTP-induced neuronal death , 2015, Cell Death and Differentiation.

[5]  Dimitri Krainc,et al.  Huntingtin cleavage product A forms in neurons and is reduced by gamma-secretase inhibitors , 2010, Molecular Neurodegeneration.

[6]  P. Greengard,et al.  Protein Tyrosine Kinase Activity and Its Endogenous Substrates in Rat Brain: A Subcellular and Regional Survey , 1988, Journal of neurochemistry.

[7]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[8]  V. Ravindranath,et al.  Selective Activation of p38 Mitogen-Activated Protein Kinase in Dopaminergic Neurons of Substantia Nigra Leads to Nuclear Translocation of p53 in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Mice , 2008, The Journal of Neuroscience.

[9]  A. Koleske,et al.  A Role for the Non-Receptor Tyrosine Kinase Abl2/Arg in Experimental Neuroinflammation , 2018, Journal of Neuroimmune Pharmacology.

[10]  Thomas C. Südhof,et al.  A Transcriptively Active Complex of APP with Fe65 and Histone Acetyltransferase Tip60 , 2001, Science.

[11]  B. Vinson,et al.  Imatinib methanesulfonate reduces hippocampal amyloid-beta and restores cognitive function following repeated endotoxin exposure , 2013, Brain, Behavior, and Immunity.

[12]  C. Kuan,et al.  Microglial-mediated PDGF-CC activation increases cerebrovascular permeability during ischemic stroke , 2017, Acta Neuropathologica.

[13]  J. Melo,et al.  Modulation of the p 38 MAPK ( mitogen-activated protein kinase ) pathway through Bcr / Abl : implications in the cellular response to AraC , 2005 .

[14]  K. Kosik,et al.  Activation of the neuronal c-Abl tyrosine kinase by amyloid-β-peptide and reactive oxygen species , 2004, Neurobiology of Disease.

[15]  Adnan I Qureshi,et al.  Intracerebral haemorrhage , 2011, Radiopaedia.org.

[16]  K. Antman,et al.  Imatinib mesylate--a new oral targeted therapy. , 2002, The New England journal of medicine.

[17]  D. Vyas,et al.  Nuclear factor kappa B role in inflammation associated gastrointestinal malignancies. , 2015, World journal of gastroenterology.

[18]  A. Easton,et al.  Modulation of blood–brain barrier permeability by neutrophils: in vitro and in vivo studies , 2009, Brain Research.

[19]  A. Giordano,et al.  Imatinib treatment inhibit IL‐6, IL‐8, NF‐KB and AP‐1 production and modulate intracellular calcium in CML patients , 2012, Journal of cellular physiology.

[20]  M. Paul,et al.  Tyrosine kinase – Role and significance in Cancer , 2004, International journal of medical sciences.

[21]  J. Richardson,et al.  The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. , 2003, Blood.

[22]  E. Masliah,et al.  Neprilysin-2 is an important β-amyloid degrading enzyme. , 2011, The American journal of pathology.

[23]  K. Blennow,et al.  Imatinib treatment and Aβ42 in humans , 2014, Alzheimer's & Dementia.

[24]  F. Checler,et al.  α-Synuclein Lowers p53-dependent Apoptotic Response of Neuronal Cells , 2002, The Journal of Biological Chemistry.

[25]  Zahiruddin Othman,et al.  Lipopolysaccharide-induced memory impairment in rats: a model of Alzheimer's disease. , 2017, Physiological research.

[26]  Y. Liu,et al.  MicroRNA-181a Regulates Apoptosis and Autophagy Process in Parkinson’s Disease by Inhibiting p38 Mitogen-Activated Protein Kinase (MAPK)/c-Jun N-Terminal Kinases (JNK) Signaling Pathways , 2017, Medical science monitor : international medical journal of experimental and clinical research.

[27]  M. Khorramizadeh,et al.  Effects of imatinib mesylate in mouse models of multiple sclerosis and in vitro determinants. , 2014, Iranian journal of allergy, asthma, and immunology.

[28]  Wei Wu,et al.  Intranasal sirna targeting c-kit reduces airway inflammation in experimental allergic asthma. , 2014, International journal of clinical and experimental pathology.

[29]  John H. Zhang,et al.  PDGFR‐α inhibition preserves blood‐brain barrier after intracerebral hemorrhage , 2011, Annals of neurology.

[30]  A. Szybińska,et al.  P53 Dysfunction in Neurodegenerative Diseases - The Cause or Effect of Pathological Changes? , 2017, Aging and disease.

[31]  I. Hussain,et al.  The Role of γ-Secretase Activating Protein (GSAP) and Imatinib in the Regulation of γ-Secretase Activity and Amyloid-β Generation* , 2012, The Journal of Biological Chemistry.

[32]  Y. Taya,et al.  A Role for the p38 Mitogen-activated Protein Kinase Pathway in the Transcriptional Activation of p53 on Genotoxic Stress by Chemotherapeutic Agents , 2000 .

[33]  O. Crespo,et al.  Tyrosine Kinase Inhibitors Ameliorate Autoimmune Encephalomyelitis in a Mouse Model of Multiple Sclerosis , 2011, Journal of Clinical Immunology.

[34]  M. Chumley,et al.  Imatinib methanesulfonate reduces hyperphosphorylation of tau following repeated peripheral exposure to lipopolysaccharide , 2016, Neuroscience.

[35]  G. Demetri,et al.  A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor , 2016, Expert opinion on drug safety.

[36]  J. Neugroschl,et al.  Alzheimer's disease: diagnosis and treatment across the spectrum of disease severity. , 2011, The Mount Sinai journal of medicine, New York.

[37]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[38]  D. Lawrence,et al.  Randomized assessment of imatinib in patients with acute ischaemic stroke treated with intravenous thrombolysis , 2017, Journal of internal medicine.

[39]  Matthias Mack,et al.  Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. , 2006, Brain : a journal of neurology.

[40]  D. Praticò,et al.  Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles. , 2014, Journal of Alzheimer's disease : JAD.

[41]  Ulf Eriksson,et al.  Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke , 2008, Nature Medicine.

[42]  J. Weinberger,et al.  Management of intracerebral hemorrhage , 2007, Vascular health and risk management.

[43]  F. Bloom,et al.  Peripheral reduction of β‐amyloid is sufficient to reduce brain β‐amyloid: Implications for Alzheimer's disease , 2011, Journal of neuroscience research.

[44]  Z. Qin,et al.  p38MAPK/p53-Mediated Bax induction contributes to neurons degeneration in rotenone-induced cellular and rat models of Parkinson’s disease , 2013, Neurochemistry International.

[45]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[46]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[47]  Danna Zhou,et al.  d. , 1840, Microbial pathogenesis.

[48]  N. Inestrosa,et al.  STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's beta-amyloid deposits. , 2008, Brain : a journal of neurology.

[49]  S. Lipton,et al.  Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease , 2014, Molecular Neurodegeneration.

[50]  David R. Croucher,et al.  t-PA, but not desmoteplase, induces plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditions , 2014, Brain Research.

[51]  Francisco Cervantes,et al.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.

[52]  John H. Zhang,et al.  Imatinib preserves blood–brain barrier integrity following experimental subarachnoid hemorrhage in rats , 2015, Journal of neuroscience research.

[53]  M. Ferrer,et al.  Reduction of Blood Amyloid-β Oligomers in Alzheimer's Disease Transgenic Mice by c-Abl Kinase Inhibition. , 2016, Journal of Alzheimer's disease : JAD.

[54]  E. Toledo,et al.  c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice , 2011, Neurobiology of Aging.

[55]  T. Dawson,et al.  Diagnosis and treatment of Parkinson disease: molecules to medicine. , 2006, The Journal of clinical investigation.

[56]  T. Dawson,et al.  Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease. , 2005, Brain research. Molecular brain research.

[57]  T. Olsson,et al.  Imatinib Ameliorates Neuroinflammation in a Rat Model of Multiple Sclerosis by Enhancing Blood-Brain Barrier Integrity and by Modulating the Peripheral Immune Response , 2013, PloS one.

[58]  R. Wade-Martins,et al.  Alpha-synuclein oligomers: a new hope , 2017, Acta Neuropathologica.

[59]  E. Su,et al.  Imatinib treatment reduces brain injury in a murine model of traumatic brain injury , 2015, Front. Cell. Neurosci..

[60]  J. A. Carson,et al.  β‐Amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? , 2002, Journal of neurochemistry.

[61]  A. Cuadrado,et al.  Mechanisms and functions of p38 MAPK signalling. , 2010, The Biochemical journal.

[62]  Pramod K. Mishra,et al.  C-Reactive Protein Increases BBB Permeability: Implications for Obesity and Neuroinflammation , 2012, Cellular Physiology and Biochemistry.

[63]  C. Link,et al.  In vivo induction of membrane damage by β-amyloid peptide oligomers , 2018, Acta Neuropathologica Communications.

[64]  M. Fehlings,et al.  Acute Spinal Cord Injury , 2015, Journal of spinal disorders & techniques.

[65]  Zhengzheng Liao,et al.  Intracerebroventricular injection of resveratrol ameliorated Aβ-induced learning and cognitive decline in mice , 2018, Metabolic Brain Disease.

[66]  Y. Ikeda,et al.  Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome‐positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid , 2002, British journal of haematology.

[67]  Paul Greengard,et al.  Gleevec inhibits β-amyloid production but not Notch cleavage , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[68]  C. Waller,et al.  Imatinib mesylate. , 2010, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[69]  M. Chumley,et al.  Prolonged elevation in hippocampal Aβ and cognitive deficits following repeated endotoxin exposure in the mouse , 2012, Behavioural Brain Research.

[70]  P. Greengard,et al.  Gamma-secretase activating protein, a therapeutic target for Alzheimer's disease , 2010, Nature.

[71]  J. Melo,et al.  Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. , 2005, The Biochemical journal.

[72]  M. Tabaton,et al.  Generation of an apoptotic intracellular peptide by gamma-secretase cleavage of Alzheimer's amyloid beta protein precursor. , 2000, Journal of Alzheimer's disease : JAD.

[73]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[74]  N. Welsh,et al.  Effects of Imatinib Mesylate (Gleevec) on Human Islet NF-kappaB Activation and Chemokine Production In Vitro , 2011, PloS one.

[75]  F. Blandini,et al.  Animal models of Parkinson’s disease , 2012, The FEBS journal.

[76]  F. Safavi,et al.  c-kit plays a critical role in induction of intravenous tolerance in experimental autoimmune encephalomyelitis , 2015, Immunologic research.

[77]  O. Forlenza,et al.  Alzheimer's disease. , 2012, Sub-cellular biochemistry.

[78]  J. Dunys,et al.  γ-Secretase-mediated regulation of neprilysin: influence of cell density and aging and modulation by imatinib. , 2011, Journal of Alzheimer's disease : JAD.

[79]  W. Taki,et al.  Imatinib mesylate prevents cerebral vasospasm after subarachnoid hemorrhage via inhibiting tenascin-C expression in rats , 2012, Neurobiology of Disease.

[80]  P. Greengard,et al.  Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage , 2017, Proceedings of the National Academy of Sciences.

[81]  F. Checler,et al.  Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. , 2002, The Journal of biological chemistry.

[82]  Emad Y Moawad.  Induction of Multiple Sclerosis and Response to Tyrosine Kinase Inhibitors , 2013, Indian Journal of Clinical Biochemistry.

[83]  Tsuyoshi Murata,et al.  {m , 1934, ACML.

[84]  T. Gasser.  Molecular pathogenesis of Parkinson disease: insights from genetic studies , 2009, Expert Reviews in Molecular Medicine.

[85]  F. LaFerla,et al.  Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[86]  R. Weichselbaum,et al.  Activation of p38 Mitogen-activated Protein Kinase by c-Abl-dependent and -independent Mechanisms* , 1996, The Journal of Biological Chemistry.

[87]  Jae Woong Lee,et al.  Journal of Neuroinflammation Neuro-inflammation Induced by Lipopolysaccharide Causes Cognitive Impairment through Enhancement of Beta-amyloid Generation , 2022 .

[88]  P. Tak,et al.  NF-κB: a key role in inflammatory diseases , 2001 .

[89]  F. Checler,et al.  Presenilin-Dependent Transcriptional Control of the Aβ-Degrading Enzyme Neprilysin by Intracellular Domains of βAPP and APLP , 2005, Neuron.

[90]  S. Y. Cajal,et al.  c‐Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin‐based therapy , 2008, International journal of cancer.

[91]  Xiaohui Xiaohui,et al.  The Role of Platelet-Derived Growth Factor Receptor in Early Brain Injury Following Subarachnoid Hemorrhage. , 2016, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[92]  F. Checler,et al.  Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. , 2005, Neuron.

[93]  Jiahuai Han,et al.  Activation and signaling of the p38 MAP kinase pathway , 2005, Cell Research.

[94]  D. Mikulis,et al.  Longitudinal Assessment of Imatinib’s Effect on the Blood–Brain Barrier After Ischemia/Reperfusion Injury with Permeability MRI , 2014, Translational Stroke Research.

[95]  Yvonne S. Eisele,et al.  Gleevec increases levels of the amyloid precursor protein intracellular domain and of the amyloid-beta degrading enzyme neprilysin. , 2007, Molecular biology of the cell.

[96]  L. Olson,et al.  Imatinib Enhances Functional Outcome after Spinal Cord Injury , 2012, PloS one.